Programmed cell death (PD-1) and its ligand (PD-L1) inhibitors have shown clinical response in many tumours. PD-L1 data are limited in head and neck cutaneous squamous cell carcinoma (HNcSCC) and no clinical trials of PD-1/PD-L1 inhibitors are published. We performed PD-L1 immunohistochemistry on 74 cases of high risk HNcSCC with 38 matched metastases and evaluated clinicopathological associations, prognostic significance and heterogeneity in matched metastases. We observed PD-L1 expression in >5% of primary tumour cells in 29 cases (39.2%), primary tumour infiltrating lymphocytes (TILs) in 40 cases (70.2%), metastatic tumour cells in 15 cases (39.5%), and metastatic TILs in 18 cases (47.4%). PD-L1 expression in >5% of primary tumour cells was associated with an inflammatory phenotype (p = 0.04), and in primary TILs with clear margins (p = 0.05). PD-L1 expression in >5% of primary tumour cells (p = 0.01), primary TILs (p = 0.001), and metastatic TILs (p = 0.02) was associated with improved disease free survival. PD-L1 expression in >5% of tumour cells was heterogeneous between primary and metastatic tumours in 13 cases (34.2%). PD-L1 expression is common in HNcSCC supporting the rationale for a clinical trial of PD-1/ PD-L1 inhibitors. PD-L1 expression in tumour cells or TILs predicts longer disease free survival and demonstrates temperospatial heterogeneity.
Immune checkpoints including Programmed Cell Death-Ligand 1 (PD-L1) and its receptor (PD-1) are inhibitory pathways that suppress host T cells and moderate the physiological immune response to limit tissue damage and maintain self-tolerance. 1 Many of these checkpoints are ligand-receptor interactions and therefore amenable to pharmacological modulation that can reactivate T cells to eliminate tumor cells. 1 The interaction between PD-L1 and PD-1 suppresses the immune system by transducing an inhibitory signal on T cell proliferation, cytokine production and cytotoxic function. 2 Clinical data for PD-1/PD-L1
inhibitors have shown response rates ranging from 10-50% in metastatic melanoma, nonsmall cell lung cancer (NSCLC), metastatic renal cell carcinoma, metastatic urothelial carcinoma, ovarian cancer, haematological malignancies and head and neck squamous cell carcinoma. 3 There is, however, no data regarding the prognostic significance of PD-L1 expression and no published clinical trials evaluating PD-1/PD-L1 inhibitors in high risk head and neck cutaneous squamous cell carcinoma (HNcSCC).
Cutaneous squamous cell carcinoma (cSCC) is one of the most common and expensive malignancies and the incidence continues to rise with the aging population. 4, 5 The vast majority of cases occur on the UV-exposed head and neck region. 6 Although most are localized and curable, advanced disease requires radical surgery and post-operative radiotherapy leading to significant functional morbidity. 7 Given this rising burden of disease and the limited systemic therapeutic options for advanced cSCC, novel treatment options such as immune checkpoint inhibitors need to be explored. 8 A recent meta-analysis demonstrated that immunohistochemical expression of PD-L1 in tumor cells was associated with clinical response to PD-1/PD-L1 inhibitors in metastatic melanoma and non-squamous NSCLC but not in renal cell carcinoma or squamous NSCLC. Clinical and follow up data:
Data on patient demographics, post-operative adjuvant therapy, local failure, regional failure, distant metastases and survival were obtained.
Histopathological review:
The archival slides from all 74 primary tumors and 38 metastases were reviewed for tumor size, depth of invasion, tumor differentiation, margins of resection, lymphovascular and perineural invasion, and for evaluation of tumor infiltrating lymphocytes. All tumors were staged using the 7 th edition of the American Joint Committee on Cancer Cancer Staging Manual pTNM staging system for primary cSCC. 
PD-L1 staining:
PD-L1 staining intensity was quantified in both cSCC and TILs as follows: no staining (0+);
weak but perceptible and convincing membranous staining (1+); moderate membranous staining (2+); strong membranous +/-cytoplasmic staining (3+) (Figure 1 ).
Statistical analysis:
Statistical analysis was performed using Stata version 11.2 (Statacorp, TX). Categorical data was analysed using the chi-square test and continuous data using the two-sample T test.
Hazard rations for clinicopathological variables were calculated using the Cox proportional hazards model. Disease-free survival was calculated from the date of surgery to date of first disease recurrence, or death. Survival curves were generated using the Kaplan-Meier method. p values less than 0.05 were considered statistically significant. PD-L1 staining percentage was initially analysed as a continuous variable in tumor cells and in TILs and then subsequently a statistically significant and clinically useful cut-off (>5%) was used for further analysis.
Results

Cohort characteristics:
The cohort included 64 males and 10 females (M:F = 6.4:1) with a median age of 69.9 years (range 34-100 years). Adjuvant radiotherapy was administered to 23 patients (31.5%), including 10 without metastases and 13 with metastases. Adjuvant chemotherapy (carboplatin) was administered to two patients (2.7%) without metastases. The median follow-up time was 2.2 years (range 0.1-7.9 years) with 32 deaths (43.2%), including six attributed to HNcSCC (Table 1) .
PD-L1 expression:
In PD-L1 expression in >5% of the cells (Table 2) .
Association between PD-L1 expression and clinicopathological variables:
In (Table 5) .
Discussion
This study is one of the first to evaluate the frequency and clinicopathological associations In the current study, PD-L1 expression in >5% of tumor cells was seen in 39 of the primary cases (52.7%) using the SP263 rabbit monoclonal antibody. The literature regarding PD-L1 expression is fraught with variable rates of PD-L1 expression that cannot be compared across studies due to the different antibody clones and cut-offs that have been employed. 3, 17, 18 For example, Slater and Googe report a 70% incidence of PD-L1 expression in primary high-risk cSCC in a cohort of 20 cases with SP142 clone and a cut-off of ≥1%; on the other hand Schaper et al report a 10.3% incidence of PD-L1 expression in primary cSCC, without risk-stratification, in a cohort of 68 cases using the E1L3N clone and a cut-off of ≥5%. [11] [12] While correlation with clinical response to PD-1/PD-L1 inhibitors is yet to be determined, the SP263 antibody was recently found by Smith et al to be a superior assay, and hence the SP263 antibody was selected for this study. 19 Our cut-off of 5% was selected because it was associated with a statistically significant improvement in DFS in this immunotherapy naïve cohort. Notably, this cut-off has also been shown in a range of tumors to predict response to PD-1/PD-L1 inhibitors. 9 Nevertheless, further data, in particular response rates to PD-1/PD-L1 inhibitors, are required from the various tumor-specific trials before the clinical validity of a given antibody clone or cut-off can be determined.
The prognostic significance of PD-L1 expression in tumor cells of primary HNcSCC has not previously been described. As an immunosuppressive molecule promoting tumor evasion, the increased expression of PD-L1 intuitively should result in a worse prognosis as is documented in gastric, breast, renal, and pancreatic cancer. [20] [21] [22] [23] However, improved prognosis has been associated with PD-L1 expression in metastatic melanoma, Merkel cell carcinoma, HPV-associated head and neck SCC, mismatch-repair-proficient colorectal cancer, NSCLC, and small cell lung cancer. [24] [25] [26] [27] [28] [29] One potential answer to this paradox is that the PD-L1 molecule is inducible by local inflammatory factors such as interferon-gamma in the tumor microenvironment, hence its expression could reflect an active, endogenous, anti-tumoral immune response. 24, 30 This may also explain the strong association of survival with TILs in both the primary and metastatic HNcSCC compared with the tumor cells. In contrast to tumor cells, there is limited data regarding the prognostic value of PD-L1 expression in TILs, however a similar effect of improved prognosis with PD-L1 expression in
TILs was reported in spinal chordoma, ovarian high grade serous carcinoma, and urothelial carcinoma. [31] [32] [33] Thus our data suggest that PD-L1 is biologically relevant in the HNcSCC tumor microenvironment, supporting a potential therapeutic role for PD-1/PD-L1 inhibitors.
PD-L1 expression in HNcSCC tumor cells was associated with an inflammatory phenotype, as has also been observed in the two other documented series of PD-L1 expression in cSCC. [11] [12] reason for this correlation is unclear, although it supports the possibility that PD-L1 positive TILs may be associated with a less infiltrative growth pattern and a more effective tumor control.
Our data demonstrate heterogeneity in PD-L1 expression in primary HNcSCC and their metastases in 34% of cases. Unlike their primary counterparts, the PD-L1 expression in metastatic tumors was not associated with survival. A similar spatial and temporal heterogeneity has been described in other malignancies such as clear cell renal carcinoma, melanoma, and lung cancer. [38] [39] [40] [41] This finding has implications for designing clinical trials and for retesting of metastatic neoplasms, which may be more or less accessible than their primary counterparts. This is particularly relevant for cSCC as the histologic material of the primary site may not be easily available for testing in many metastatic cases.
Currently, there are no tumor-specific trials of PD-1/PD-L1 inhibitor in cutaneous SCC. In a review article of multiple tumor types, Patel and Kurzrock suggest that tumor types classically responding to PD-1/PD-L1 inhibitors tend to have higher rates of PD-L1 expression by immunohistochemistry than tumor types with typically poor responses. 18 This supports the rationale for a trial of PD-1/PD-L1 inhibitors in HNcSCC. The argument is strengthened by several inherent characteristics of cSCC including its high mutational burden and its immunogenic nature, where immunosuppression confers a 65 times increased risk of developing cSCC in solid organ transplant recipients; both of which are described as being positively associated with response to PD-1/PD-L1 inhibitors. [42] [43] [44] [45] Furthermore, murine studies and six independent case reports have shown responses to PD-1/PD-L1 inhibitors in unresectable cSCC ranging from disease stabilisation to complete response. [46] [47] [48] [49] In conclusion, this is the largest HNcSCC tumor series to date to evaluate PD-L1 expression and the first to report an association with survival. PD-L1 expression is common in tumor cells and TILs and provides further evidence for a clinical trial of PD-1/PD-L1 inhibitors in
HNcSCC. We also demonstrate that PD-L1 expression in >5% of primary tumor cells, primary
TILs, and metastatic TILs is associated with an improved DFS in HNcSCC.
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